PortfoliosLab logoPortfoliosLab logo
AMLX vs. DCTH
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AMLX vs. DCTH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amylyx Pharmaceuticals, Inc. (AMLX) and Delcath Systems, Inc. (DCTH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AMLX achieves a 34.77% return, which is significantly higher than DCTH's 13.96% return.


AMLX

1D
3.89%
1M
19.88%
YTD
34.77%
6M
30.24%
1Y
222.38%
3Y*
-10.96%
5Y*
10Y*

DCTH

1D
-1.54%
1M
4.45%
YTD
13.96%
6M
14.30%
1Y
-16.90%
3Y*
27.37%
5Y*
1.93%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

AMLX vs. DCTH - Yearly Performance Comparison


2026 (YTD)2025202420232022
AMLX
Amylyx Pharmaceuticals, Inc.
34.77%219.58%-74.32%-60.16%75.95%
DCTH
Delcath Systems, Inc.
13.96%-16.11%189.42%15.56%-51.09%

Correlation

The correlation between AMLX and DCTH is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.36

Correlation (3Y)
Calculated over the trailing 3-year period

0.25

Correlation (All Time)
Calculated using the full available price history since Jan 7, 2022

0.18

The correlation between AMLX and DCTH shifts across timeframes, from 0.18 (all time) to 0.36 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

AMLX:

$1.80B

DCTH:

$414.60M

EPS

AMLX:

-$1.55

DCTH:

$0.01

PB Ratio

AMLX:

6.59

DCTH:

3.68

Total Revenue (TTM)

AMLX:

$0.00

DCTH:

$65.45M

Gross Profit (TTM)

AMLX:

-$20.10M

DCTH:

$77.75M

EBITDA (TTM)

AMLX:

-$150.30M

DCTH:

$222.00K

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AMLX vs. DCTH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMLX
AMLX Risk / Return Rank: 9494
Overall Rank
AMLX Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
AMLX Sortino Ratio Rank: 9595
Sortino Ratio Rank
AMLX Omega Ratio Rank: 9191
Omega Ratio Rank
AMLX Calmar Ratio Rank: 9696
Calmar Ratio Rank
AMLX Martin Ratio Rank: 9494
Martin Ratio Rank

DCTH
DCTH Risk / Return Rank: 2828
Overall Rank
DCTH Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
DCTH Sortino Ratio Rank: 2727
Sortino Ratio Rank
DCTH Omega Ratio Rank: 2727
Omega Ratio Rank
DCTH Calmar Ratio Rank: 2828
Calmar Ratio Rank
DCTH Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AMLX vs. DCTH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and Delcath Systems, Inc. (DCTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AMLXDCTHDifference
Sharpe ratioReturn per unit of total volatility

+3.67

Sortino ratioReturn per unit of downside risk

+4.03

Omega ratioGain probability vs. loss probability

1.44

0.98

+0.46

Calmar ratioReturn relative to maximum drawdown

7.31

-0.41

+7.72

Martin ratioReturn relative to average drawdown

15.68

-0.64

+16.32

AMLX vs. DCTH - Sharpe Ratio Comparison

The current AMLX Sharpe Ratio is 3.33, which is higher than the DCTH Sharpe Ratio of -0.34. The chart below compares the historical Sharpe Ratios of AMLX and DCTH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AMLX vs. DCTH - Drawdown Comparison

The maximum AMLX drawdown since its inception was -96.04%, roughly equal to the maximum DCTH drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for AMLX and DCTH.


Loading charts...

Drawdown Indicators


AMLXDCTHDifference

Max Drawdown

Largest peak-to-trough decline

-96.04%

-99.96%

+3.92%

Max Drawdown (1Y)

Largest decline over 1 year

-30.61%

-41.71%

+11.10%

Max Drawdown (3Y)

Largest decline over 3 years

-93.09%

-62.87%

-30.22%

Max Drawdown (5Y)

Largest decline over 5 years

-82.21%

Current Drawdown

Current decline from peak

-60.22%

-99.81%

+39.59%

Average Drawdown

Average peak-to-trough decline

-59.40%

-96.43%

+37.03%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.25%

26.33%

-12.08%

Volatility

AMLX vs. DCTH - Volatility Comparison

Amylyx Pharmaceuticals, Inc. (AMLX) has a higher volatility of 16.44% compared to Delcath Systems, Inc. (DCTH) at 13.30%. This indicates that AMLX's price experiences larger fluctuations and is considered to be riskier than DCTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AMLXDCTHDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.44%

13.30%

+3.14%

Volatility (6M)

Calculated over the trailing 6-month period

43.21%

32.57%

+10.64%

Volatility (1Y)

Calculated over the trailing 1-year period

67.39%

49.63%

+17.76%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.47%

73.00%

+18.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

91.47%

109.86%

-18.39%

Dividends

AMLX vs. DCTH - Dividend Comparison

Neither AMLX nor DCTH has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

AMLX vs. DCTH - Financials Comparison

This section allows you to compare key financial metrics between Amylyx Pharmaceuticals, Inc. and Delcath Systems, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M2022202320242025202600
(AMLX) Total Revenue
(DCTH) Total Revenue
Values in USD except per share items

Frequently Asked Questions


AMLX and DCTH have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AMLX has higher volatility (16.44%) compared to DCTH (13.30%). In terms of maximum drawdown, AMLX dropped -96.04% vs DCTH's -99.96%.

AMLX currently has the higher Sharpe Ratio (3.33 vs -0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AMLX and DCTH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer